Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nicola Polverelli is active.

Publication


Featured researches published by Nicola Polverelli.


Haematologica | 2013

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

Nicola Vianelli; Francesca Palandri; Nicola Polverelli; Roberto Stasi; Joel Joelsson; Eva Johansson; Marco Ruggeri; Francesco Zaja; Silvia Cantoni; Angelo Emanuele Catucci; Anna Candoni; Enrica Morra; Magnus Björkholm; Michele Baccarani; Francesco Rodeghiero

The treatment of choice in steroid-resistant immune thrombocytopenia is still controversial due to the recent advent of new drugs (anti-CD20 antibodies and thrombopoietin mimetics) that have encouraged a generalized tendency to delay splenectomy. Consequently, it is extremely importance to define the efficacy and safety of splenectomy in the long term. We retrospectively analyzed the data of 233 patients affected by immune thrombocytopenia who underwent splenectomy between 1959 and 2001 in 6 European hematologic institutions and who have now a minimum follow up of ten years from surgery. Of the 233 patients, 180 (77%) achieved a complete response and 26 (11%) a response. Sixty-eight of 206 (33%) responsive patients relapsed, mostly (75%) within four years from first response. In 92 patients (39.5%), further treatment was required after splenectomy that was effective in 76 cases (83%). In 138 patients (59%), response was maintained free of any treatment at last contact. No significant association between baseline characteristics and likelihood of stable response was found. Overall, 73 (31%) and 58 (25%) patients experienced at least one infectious or hemorrhagic complication, which was fatal in 2 and 3 patients, respectively. A stable response to splenectomy was associated with a lower rate of infections (P=0.004) and hemorrhages (P<0.0001). Thrombosis developed in 18 patients (8%) and was fatal in 4. Splenectomy achieved a long-term stable response in approximately 60% of cases. Complications mainly affected non-responding patients and were fatal in a minority.


American Journal of Hematology | 2009

Long-term follow-up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy†

Francesca Palandri; Lucia Catani; Nicoletta Testoni; Emanuela Ottaviani; Nicola Polverelli; Mauro Fiacchini; Antonio De Vivo; Federica Salmi; Alessandro Lucchesi; Michele Baccarani; Nicola Vianelli

Cytotoxic agents like Hydroxyurea, Busulfan and Interferon‐alpha are to date the most commonly used therapeutic approaches in Essential Thrombocythemia (ET). However, few data on the efficacy and safety of these agents in the long‐term are currently available. We report a retrospective analysis of the long‐term outcome of 386 consecutive ET patients, followed at single Institution for a median follow‐up of 9.5 years (range, 3–28.5). Cytoreductive therapy was administered to 338 patients (88%), obtaining a response in 86% of cases. Forty‐five patients (12%) experienced a thrombosis. Among baseline characteristics, only history of vascular events prior to ET diagnosis predicted a higher incidence of thrombosis. Evolution in acute leukemia/myelofibrosis occurred in 6 (1,5%) and 20 (5%) patients, and was significantly higher in patients receiving sequential cytotoxic agents. Overall survival was 38% at 19 years and was poorer for patients older than 60 years, with higher leukocytes count (>15 × 109/L), hypertension and mellitus diabetes at ET diagnosis and for patients experiencing a thrombotic event during follow‐up. Cytoreductive therapy was effective in decreasing platelet number with negligible toxicity; however, thrombocytosis control did not reduce the incidence of thrombosis and, for patients who received sequential therapies, the probability of disease evolution was higher and survival was poorer. Am. J. Hematol. 2009.


Journal of Thrombosis and Haemostasis | 2014

Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors

Marco Ruggeri; Alberto Tosetto; Francesca Palandri; Nicola Polverelli; Maria Gabriella Mazzucconi; Cristina Santoro; Gianluca Gaidano; Monia Lunghi; Francesco Zaja; V. De Stefano; Roberto Sartori; P. Fazi; Francesco Rodeghiero

An increased risk of thrombosis has been reported in primary immune thrombocytopenia (ITP) and with the use of thrombopoietin (TPO) receptor agonists, on the basis of population studies using administrative databases.


Annals of Hematology | 2013

Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia

Lucia Catani; Daria Sollazzo; Sara Trabanelli; Antonio Curti; Cecilia Evangelisti; Nicola Polverelli; Francesca Palandri; Michele Baccarani; Nicola Vianelli; Roberto M. Lemoli

Along with their immunogenic role, dendritic cells (DCs) are also critical in maintaining tolerance to self-antigens by inducing regulatory T cells (Tregs) via the expression of the immunomodulatory enzyme indoleamine 2,3-dioxygenase 1 (IDO1). In turn, Tregs modulate the maturation and/or function of DCs. In immune thrombocytopenia (ITP), the interaction between DCs and Tregs has never been investigated although decreased number/function of Tregs as well as altered DCs have been described. Here, we ask whether, in ITP: (1) IDO1 expression/activity is decreased in mature DCs; (2) IDO1-mediated Treg generation is impaired; and (3) DC maturation is abnormally modulated by Tregs. We found that in ITP, DCs show reduced capability of upregulating the expression/activity of IDO1. This finding results in the reduced ability of mature DCs of converting T cells into Tregs. In turn, Tregs are characterized by decreased interleukin-10 production and show lower ability of inhibiting DC maturation. In conclusion, these data point out the role of IDO1 in the impaired regulatory T cell development of ITP patients and suggest that the cross-talk between Tregs and DCs is hampered and plays a pathogenetic role.


Leukemia | 2015

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

Francesca Palandri; Roberto Latagliata; Nicola Polverelli; Alessia Tieghi; Monica Crugnola; Bruno Martino; Margherita Perricone; Massimo Breccia; Emanuela Ottaviani; Nicoletta Testoni; Francesco Merli; Franco Aversa; Giuliana Alimena; Michele Cavo; Giovanni Martinelli; Lucia Catani; Michele Baccarani; Nicola Vianelli

We investigated the influence of molecular status on disease characteristics and clinical outcome in young patients (⩽40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) or early/prefibrotic primary myelofibrosis (early-PMF). Overall, 217 patients with ET (number 197) and early-PMF (number 20) were included in the analysis. Median follow-up time was 10.2 years. The cumulative incidence of thrombosis, hemorrhages and disease evolution into myelofibrosis/acute leukemia were 16.6%, 8.6% and 3% at 15 years, respectively. No differences were detectable between ET and early-PMF patients, although the latter cohort showed a trend for worse combined-event free survival (EFS). Mutation frequency were 61% for JAK2V617F, 25% for CALR and 1% for MPLW515K, and were comparable across WHO diagnosis; however, JAK2V617F allele burden was higher in the early-PMF group. Compared with JAK2V617F-positive patients, CALR-mutated patients displayed higher platelet count and lower hemoglobin level. CALR mutations significantly correlated with lower thrombotic risk (9.1% versus 21.7%, P=0.04), longer survival (100% versus 96%, P=0.05) and better combined-EFS (86% versus 71%, P=0.02). However, non-type 1/type 2 CALR mutations (‘minor’ mutations) and abnormal karyotype were found to correlate with increased risk of disease evolution. At last contact, six patients had died; in five cases, the causes of death were related to the hematological disease and occurred at a median age of 64 years (range: 53–68 years). Twenty-eight patients (13%) were unmutated for JAK2, CALR and MPL: no event was registered in these ‘triple-negative’ patients.


Leukemia & Lymphoma | 2009

JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

Francesca Palandri; Emanuela Ottaviani; Federica Salmi; Lucia Catani; Nicola Polverelli; Mauro Fiacchini; Giovanni Martinelli; Michele Baccarani; Nicola Vianelli

The JAK2V617F mutation occurs in 50% of patients with essential thrombocythemia (ET). We investigated the correlation between the JAK2V617F mutation and clinical and laboratory characteristics, thrombohemorrhagic risk and incidence of disease evolution in 275 patients with ET followed for a median follow-up of 7 years. JAK2V617F mutation was detected in 175 patients (64%), of whom 173 were heterozygous. Patients with the mutation were older and displayed higher hemoglobin and hematocrit levels, but lower platelet count. Cytotoxic treatment requirement was similar in the two groups, but patients with the mutation showed better responses. Incidence of thrombosis and disease evolution was comparable. JAK2 mutational status assessment was valuable to distinguish two populations of patients with ET, showing distinctive hematologic and clinical features.


American Journal of Hematology | 2014

Pregnancy complications predict thrombotic events in young women with essential thrombocythemia

Maria Luigia Randi; Irene Bertozzi; Elisa Rumi; Chiara Elena; Guido Finazzi; Nicola Vianelli; Nicola Polverelli; Marco Ruggeri; Alessandro M. Vannucchi; Elisabetta Antonioli; Federico Lussana; Alessia Tieghi; Elena Elli; Marco Ruella; Fabrizio Fabris; Mario Cazzola; Tiziano Barbui

Although Philadelphia‐negative myeloproliferative neoplasms (MPNs) occur typically in middle to advanced age, any age group may be affected, posing a challenge for their management during pregnancy when they occur in young females. There is a high incidence of thromboembolic events and pregnancy complications in patients with myeloproliferative neoplasms, and a possible relationship between these complications is a matter of concern. The aim of this article was to correlate thrombosis and pregnancy outcome in 158 females with ET experiencing 237 pregnancies. Seven patients had a thrombotic event before their first pregnancy, one of them ended (14.3%) in a miscarriage. Among the 151 patients with no history of thrombosis before they became pregnant, 40 (26.5%) had a miscarriage (P = NS). Eighteen patients (11.4%) developed major thrombotic complications (12 splanchnic vein, 1 cerebral vein, 2 coronary syndromes, and 3 strokes) after at least one pregnancy (4 uneventful and 14 complicated). The occurrence of thrombosis was significantly more frequent (P < 0.001) in patients with a history of pregnancy complications (28%) than in those experiencing a normal pregnancy and delivery (3.7%). Pregnancy complications in women with ET are associated with a higher risk of subsequent thromboses, so pregnant women with this neoplasm who miscarry need to be carefully monitored. Am. J. Hematol. 89:306–309, 2014.


American Journal of Hematology | 2016

Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years

Francesca Palandri; Nicola Polverelli; Daria Sollazzo; Marco Romano; Lucia Catani; Michele Cavo; Nicola Vianelli

In the last years, rituximab (RTX) and agonists of the thrombopoietin receptor (TPO‐R) eltrombopag and romiplostim have provided new treatment options in persistent and chronic immune thrombocytopenia (ITP). Here, we analyzed the changes in therapeutic choices over time and their impact on clinical outcomes in a cohort of 557 ITP outpatients followed at the “L. and A. Seràgnoli” Institute of Hematology, Bologna, Italy, from 1980 to 2015. Overall 397 patients (71%) required front‐line corticosteroids, mainly prednisone. Over the decades, splenectomy was delayed from second to third‐line, but was steadily used in around 15–25% of patients refractory or relapsing after first‐line treatment. Consensually, RTX and TPO‐R agonists emerged as second and third‐line therapy of choice, respectively. Splenectomy was associated with the best response rates and the lower incidences of relapse, while the relapse rate after RTX was comparable to that observed with corticosteroids and other immunosuppressive agents. The introduction of TPO‐R agonists gave an alternative to the administration of immunosuppressive drugs and probably contributed to moderate the incidence of infectious complications that remained stable over the decades, despite an increasing use of RTX from the 2000s onwards. Overall responses were similar over time, with over 97% achieving a response in all time‐periods. However, the cumulative risk of bleeding significantly decreased [14.3% (1980–89) vs. 7% (1990–99) vs. 5.6% (2000–09) vs. 0.2% (2010–15)] (P < 0.001), mainly thanks to the optimization of front‐line corticosteroids therapy and to the wider availability of second and third‐line therapies. Am. J. Hematol. 91:E267–E272, 2016.


British Journal of Haematology | 2014

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera

Federico Lussana; Alessandra Carobbio; Maria Luigia Randi; Chiara Elena; Elisa Rumi; Guido Finazzi; Irene Bertozzi; Lisa Pieri; Marco Ruggeri; Francesca Palandri; Nicola Polverelli; Elena Elli; Alessia Tieghi; Marco Ruella; Mario Cazzola; Alessandro Rambaldi; Alessandro M. Vannucchi; Tiziano Barbui

In patients who do not meet the World Health Organization (WHO) criteria for overt polycythaemia vera (PV), a diagnosis of masked PV (mPV) can be determined. A fraction of mPV patients may display thrombocytosis, thus mimicking essential thrombocythaemia (ET). No previous studies have examined clinical outcomes of mPV among young JAK2‐mutated patients. We analysed a retrospective cohort of 538 JAK2‐mutated patients younger than 40 years, after a re‐assessment of the diagnosis according to the haemoglobin threshold for mPV. In this cohort of patients, 97 (18%) met the WHO criteria for PV, 66 patients (12%) were classified as mPV and 375 (70%) as JAK2‐mutated ET. Surprisingly, a significant difference in the incidence of thrombosis was found when comparing mPV versus overt PV patients (P = 0·04). In multivariate analysis, the only factor accounting for the difference in the risk of thrombosis was the less frequent use of phlebotomies and cytoreduction in mPV patients compared to those with overt PV. Thus, we emphasize the need for the identification of mPV in young JAK2‐mutated patients in order to optimize their treatments.


American Journal of Hematology | 2017

Risk Factors for Infections In Myelofibrosis: Role of Disease Status and Treatment. A multicenter study of 507 patients

Nicola Polverelli; Massimo Breccia; Giulia Benevolo; Bruno Martino; Alessia Tieghi; Roberto Latagliata; Elena Sabattini; Mara Riminucci; Laura Godio; Lucia Catani; Maura Nicolosi; Margherita Perricone; Daria Sollazzo; Gioia Colafigli; Anna Campana; Francesco Merli; Umberto Vitolo; Giuliana Alimena; Giovanni Martinelli; Russell E. Lewis; Nicola Vianelli; Michele Cavo; Francesca Palandri

Although infectious complications represent a relevant cause of morbidity and mortality in patients with myelofibrosis (MF), little is known about their incidence, outcome and risk factors. We retrospectively evaluated a cohort of 507 MF patients, diagnosed between 1980 and 2014 in five Italian hematology centers, to define the epidemiology of infections and describe the impact of ruxolitinib (RUX) treatment. Overall, 112 patients (22%) experienced 160 infectious events (grade 3–4, 45%) for an incidence rate of 3.9% per patient‐year. Infections were mainly bacterial (78%) and involving the respiratory tract (52% of cases). Also, viral (11%) and fungal infections (2%) were recorded. Overall, infections were fatal in 9% of the cases. Among baseline features, high/intermediate‐2 IPSS category (HR 1.8, 95%CI:1.2–2.7; P = 0.02) and spleen length ≥10 cm below left costal margin (HR 1.6, 95%CI:1.1–2.5; P = 0.04) were associated with higher infectious risk in multivariate analysis. Overall, the rate of infections was higher in the cohort of 128 RUX‐treated patients (44% vs. 20%, P < 0.001). In conclusion, IPSS‐category and splenomegaly, emerged as the main risk factors for infections in MF. RUX‐treated patients experienced significantly more infection episodes; however, future prospective studies are needed to isolate the confounding contribution of other risk factors such as disease stage. Am. J. Hematol. 92:37–41, 2017.

Collaboration


Dive into the Nicola Polverelli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alessia Tieghi

Santa Maria Nuova Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge